Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Amgen Inc. is conducting a Phase 3 study titled A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity. The study aims to demonstrate that maridebart cafraglutide is more effective than a placebo in reducing cardiovascular morbidity and mortality when used alongside standard care in patients with atherosclerotic cardiovascular disease and obesity. This study is significant as it targets a major health concern, potentially offering a new treatment avenue.
Intervention/Treatment: The study tests maridebart cafraglutide, an experimental drug administered subcutaneously, against a placebo. The drug is intended to improve cardiovascular outcomes in the targeted patient group.
Study Design: This interventional study is randomized with a parallel assignment model. It employs double masking, meaning both participants and investigators are unaware of the group assignments. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on July 25, 2025, with its primary completion and estimated overall completion dates yet to be announced. The last update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
Market Implications: The successful outcome of this study could positively impact Amgen’s stock performance, as it would enhance their cardiovascular treatment portfolio. This development may also influence investor sentiment positively, especially if maridebart cafraglutide proves to be a breakthrough in cardiovascular treatment. Competitors in the cardiovascular drug market may need to adjust their strategies accordingly.
The study is currently ongoing, with further details available on the ClinicalTrials portal.